Market Analysis and Insights: Global Immunosuppressants API Market
Due to the COVID-19 pandemic, the global Immunosuppressants API market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Corticosteroids accounting for % of the Immunosuppressants API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Autoimmune Disease segment is altered to an % CAGR throughout this forecast period.
China Immunosuppressants API market size is valued at US$ million in 2021, while the US and Europe Immunosuppressants API are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Immunosuppressants API landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Immunosuppressants API include Biocon Ltd., NATCO Pharma Limited, Triveni Interchem Private Limited, Concord Biotech Ltd., RPG Life Sciences Limited, Jiangsu Jiuyang Bio-PharmaceuticalCo. Ltd, Chunghwa Chemical Synthesis & BiotechCo. Ltd., AbbVie Inc. and Pfizer Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Immunosuppressants API Scope and Segment
Immunosuppressants API market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Immunosuppressants API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Corticosteroids
Janus kinase inhibitor
Calcineurin inhibitors
mTOR inhibitor
IMDH inhibitor
Biologics
Monoclonal antibodies
Segment by Application
Autoimmune Disease
Organ Transplant
Others
By Company
Biocon Ltd.
NATCO Pharma Limited
Triveni Interchem Private Limited
Concord Biotech Ltd.
RPG Life Sciences Limited
Jiangsu Jiuyang Bio-PharmaceuticalCo. Ltd
Chunghwa Chemical Synthesis & BiotechCo. Ltd.
AbbVie Inc.
Pfizer Inc.
Zhejiang Hisun PharmaceuticalCo Ltd
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE